All In Biotech

Free tool

FAERS Monitor: Eysuvis

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 210933 or its brand name (Eysuvis, Loteprednol Etabonate). Reports on generic versions are filed under their own applications.

Reports

1,098

Serious

306

28% of reports

Hospitalization

89

Death reported

15

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • eye pain232
  • eye irritation153
  • off label use100
  • drug ineffective95
  • ocular hyperaemia75
  • product dose omission issue74
  • headache64
  • vision blurred60
  • photophobia52
  • fatigue51
  • ocular discomfort50
  • eye swelling46
  • dry eye44
  • pruritus39
  • lacrimation increased36

Reports by year received

View as table
YearReports
20043
20053
20081
20092
20104
20112
20123
20135
20143
20158
20165
20176
201812
201920
202031
2021107
2022141
2023159
2024185
2025248
2026150

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,061 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
ocular discomfortSignal5085.765.34,084
eye painSignal23279.170.517,784
photophobiaSignal5253.140.72,601
eye irritationSignal15351.144.17,459
ocular hyperaemiaSignal7530.324.42,099
eye swellingSignal4623.717.9979
lacrimation increasedSignal3622.816.6731
dry eyeSignal4416.912.6643
vision blurredSignal608.46.5385
product dose omission issueSignal744.83.9223
off label useSignal1002.21.866
headache642.01.530
pruritus391.91.417
drug ineffective951.41.110
fatigue511.31.02

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.